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Terapia antyangiogenna w raku jajnika – dla kogo i kiedy?
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Tumor angiogenesis appears to be an important process in epithelial ovarian cancer development. Bevacizumab is 
a monoclonal antibody that can neutralize vascular endothelial growth factor, a promoter of the initiation phase of 
angiogenesis. First-line chemotherapy in combination with bevacizumab followed by maintenance bevacizumab 
demonstrated efficacy over chemotherapy alone in two phase III trials (Gynecologic Oncology Group, GOG 218 and 
ICON7); however, absolute progression-free survival benefit remains modest, with no demonstrated impact on overall 
survival. The addition of molecularly targeted agents to the treatment of women with recurrent and platinum-sensitive 
disease has been recently reported in the OCEANS study, which evaluated the benefit of adding bevacizumab to carboplatin 
and gemcitabine in women with platinum-sensitive recurrent disease. Bevacizumab-based therapy also extended progression-
free survival from 8 to 12 months. However, overall survival was not different between the two arms. In the Gynecologic 
Oncology Group 213 (GOG 213) trial, women with platinum-sensitive recurrent epithelial ovarian cancer were randomly 
assigned to medical treatment (carboplatin plus paclitaxel with or without bevacizumab). A significant improvement 
in progression-free survival (14 versus 10 months, respectively) was observed. A trend towards a significant improvement 
in overall survival, which was not statistically significant, was reported. In November 14, 2014, based on AURELIA findings, 
the Food and Drug Administration approved bevacizumab in combination with paclitaxel, pegylated liposomal doxorubicin, 
or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer. Ovarian cancer is 
a primary cancer against which these new agents are being tested. This review will describe the role of angiogenesis inhibitors 
in epithelial ovarian cancer.
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Angiogeneza nowotworowa wydaje się istotnym procesem w rozwoju raka jajnika. Bewacyzumab jest przeciwciałem 
monoklonalnym zdolnym do neutralizacji naczyniowo-śródbłonkowego czynnika wzrostu, promotora początkowej fazy 
angiogenezy. W dwóch badaniach klinicznych III fazy (Gynecologic Oncology Group – GOG 218 oraz ICON7) wykazano 
skuteczność chemioterapii pierwszego rzutu w skojarzeniu z bewacyzumabem i następowym leczeniem podtrzymującym 
bewacyzumabem w porównaniu z samą chemioterapią, jednak bezwzględne korzyści czasu wolnego bez progresji pozostają 
niewielkie, bez wpływu na przeżycie całkowite. W  badaniu OCEANS oceniono korzyści wynikające z  włączenia 
bewacyzumabu do terapii karboplatyną i gemcytabiną u kobiet z nawrotowym rakiem jajnika wrażliwym na platynę. Leczenie 
oparte na bewacyzumabie wydłużyło czas przeżycia bez progresji choroby z 8 do 12 miesięcy. Nie stwierdzono różnicy 
w odniesieniu do przeżycia całkowitego między dwiema grupami pacjentek. W badaniu klinicznym GOG 213 (Gynecologic 
Oncology Group 213) kobietom z nawrotowym rakiem jajnika wrażliwym na platynę losowo przypisywano rodzaj leczenia 
(karboplatynę plus paklitaksel z lub bez bewacyzumabu). Zaobserwowano istotną poprawę w zakresie przeżycia bez progresji 
choroby (odpowiednio 14 i 10 miesięcy). Odnotowano tendencję do poprawy w zakresie przeżycia ogólnego, jednak bez 
istotności statystycznej. W oparciu o wyniki badania AURELIA 14 listopada 2014 roku Agencja Żywności i Leków 
zatwierdziła bewacizumab w skojarzeniu z paklitakselem, pegylowaną liposomalną doksorubicyną lub topotekanem 
w leczeniu chorych z wrażliwym na platynę nawrotowym rakiem jajnika. Rak jajnika jest pierwszym nowotworem, wobec 
którego badane są te leki. W niniejszej pracy opisano rolę inhibitorów angiogenezy w nabłonkowym raku jajnika.
Słowa kluczowe: leki antyangiogenne, rak jajnika, bewacizumab
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WHAT IS THE OPTIMAL SETTING 
FOR BEVACIZUMAB TREATMENT?
Questions regarding the optimal timing of bevacizumab in 
ovarian cancer continue to emerge. When should we start 
bevacizumab in ovarian cancer?
A.  First-line chemotherapy for advanced (stage III or IV) 
EOC.
B.  Platinum-resistant EOC.
C.  Platinum-sensitive EOC.
Addition of bevacizumab to standard chemotherapy 
in four randomized, double-blind, phase III trials have 
been performed both as front-line treatment (GOG 218(4) 
INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy, with 238,700 new cases and 151,900 deaths in 2012(1). Despite optimal 
upfront surgery and the administration of front-line pacli-
taxel–carboplatin chemotherapy, ∼70% of patients will 
relapse in the first 3 years(2). Therefore, there is a strong 
need for effective first-line treatment that will increase 
response rates and progression-free survival (PFS). 
The primary goals of systemic treatment for advanced 
ovarian cancer include prolongation of survival, reduc-
tion of tumor burden, alleviation of symptoms associated 
with the disease, and minimization of toxicities associ-
ated with treatment(3). Angiogenesis has an important role 
in normal ovarian physiology, pathogenesis of epithelial 
ovarian cancers, development of ascites and metastasis as 
well as plays an active part in the treatment of EOC via 
angiogenesis inhibitors (Fig. 1). Several therapeutic strat-
egies to target angiogenesis in ovarian cancer are under 
investigation, including small molecular tyrosine kinase 
inhibitors of vascular endothelial growth factor recep-
tor (VEGFR), vascular endothelial growth factor (VEGF) 
Trap (a soluble decoy VEGF receptor), trebananib (pep-
tide-Fc fusion protein blocking angiopoietin 1/2-Tie2 
receptor interaction), synthetic f lavonoids impairing 
tumor vascularity and tubulin binders (Tab. 1). Bevaci-
zumab is a human monoclonal antibody that binds to 
and neutralizes biological activities of VEGF isoforms. 
It inhibits the formation of new vessels and suppresses 
tumor growth and metastasis by leading to regression of 
tumor vascularity. It is the most successful antiangiogenic 
agent developed to date.
Fig. 1  A. The formation of tumor-associated vasculature, formed by the process of neoangiogenesis, is critical, rate-limiting determinant of 
the growth of all tumors larger in size than approximately 0.2 mm. B–C. Vascular endothelial growth factor (also known as VEGF-A) 
is one of the most potent angiogenic factors described and stimulates endothelial cells proliferation, survival, chemotaxis, and vessel 
permeability. D. Antiangiogenic therapy relies on stopping the formation of new capillary vessels around a tumor and breaking up the 
existing network of abnormal capillaries that feed the growing cancerous mass, thereby both starving it of nutrients and cutting off the 
pathway for primary metastasis through the endogenous circulatory system
Drug Main molecular targets
Bevacizumab VEGF-A
VEGF Trap VEGF-A (B, C, D, E)
Cediranib VEGFR-1, VEGFR-2, VEGFR-3
Pazopanib VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α/β, c-kit
Trebananib Angiopoietin 1 and 2
Nintedanib VEGFR-1, VEGFR-2, and VEGFR-3, PDGFR-α/β, FGFR-1, 
FGFR-2, FGFR-3, members of the v-src
sarcoma viral oncogene homolog (Src)
family, and Flt-3
VEGF – vascular endothelial growth factor; VEGFR – vascular endothelial 
growth factor receptor; PDGFR  – platelet-derived endothelial cell growth 
factor receptor; Flt-3 – fms-like tyrosine kinase 3.
Tab. 1. Targeted pathway angiogenesis for ovarian cancer
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and ICON7(5)) as well as in patients with recurrent dis-
ease (OCEANS(6) and AURELIA(7)) (Tab. 2). In these four 
studies, the PFS was prolonged, while the overall survival 
(OS) improved in certain subgroups only in two stud-
ies. In ICON7 patients at high risk for progression (FIGO 
stage IV disease or FIGO stage III disease and >1.0 cm 
of residual disease after debulking surgery), the benefit 
of adding bevacizumab was associated with improvement 
in OS(5). In GOG 213, the OS was increased in women with 
platinum-sensitive recurrent ovarian cancer who were 
treated with chemotherapy plus bevacizumab(8).
What explains the relatively short-lived responses 
observed in the clinical setting, given that bevacizumab 
clearly increases PFS in ovarian cancer? Compensatory 
signaling through alternative proangiogenic pathways 
(e.g.  fibroblast growth factor, angiopoietin 1 – Ang1, 
delta-like ligand 4/Notch, and microRNAs) is likely to be 
a major factor in acquired resistance to bevacizumab(9).
Tumors or ischemic tissues recruit proangiogenic endo-
thelial cells and inf lammatory cells independent of 
VEGF; the recruited cells may produce several proangio-
genic molecules to rescue vascularization upon VEGF 
blockage(10).
BEVACIZUMAB AS FIRST-LINE TREATMENT 
IN OVARIAN CANCER
GOG 218 was a randomized placebo-controlled study 
involving almost 1,900 women with stage III or IV EOC 
who had undergone surgical cytoreduction(4). It was 
a three-arm trial designed to compare chemotherapy 
(carboplatin plus paclitaxel) alone (Arm 1) with che-
motherapy plus bevacizumab (Arm 2) and with che-
motherapy plus bevacizumab followed by maintenance 
bevacizumab (Arm  3). The ICON7 trial randomly 
assigned 1,528 patients with high-risk early stage or 
advanced stage ovarian cancer to carboplatin AUC 5–6 
and paclitaxel 175 mg/m2 every 3 weeks with or without 
bevacizumab 7.5 mg/kg followed by bevacizumab main-
tenance treatment(5).
In the GOG 218 study, PFS was significantly prolonged 
when bevacizumab was used concurrently and after che-
motherapy compared to chemotherapy alone (median 
14.1 vs. 10.3 months)(4). There was no improvement in 
OS with bevacizumab in either arm receiving the drug. 
The addition of bevacizumab resulted in a significantly 
prolonged PFS in the ICON-7 study (19.8 vs. 17.4 months). 
In women at high risk of progression (stage III disease 
with >1.0 cm residual disease following surgery, inoper-
able patients with stage III and stage IV disease), beva-
cizumab was associated with improvement in OS (39.3 
vs. 34.5 months)(5). While the GOG 218 study is a pla-
cebo controlled study with three study arms, ICON7 is 
a trial with two arms without placebo including stage I/II 
patients. It remains a major question as to why such sig-
nificant gains in PFS seen in the completed phase III trials 
with bevacizumab and chemotherapy frequently did not 
correspond to significant gains in OS.
GOG 218 showed that there was no benefit of the combi-
nation of bevacizumab with chemotherapy without sub-
sequent bevacizumab maintenance (11 vs. 10 months), but 
median PFS advantage of bevacizumab added to chemo-
therapy followed by maintenance treatment compared with 
chemotherapy alone (plus placebo in GOG 218) in first-
line was 3.8 months (GOG 218, from 10.3 to 14.1 months 
with and without bevacizumab), and 2 months (ICON7, 
from 22 to 24 months). The lower increase in PFS achieved 
in ICON7 compared to GOG 218 may be secondary to the 
Trial Arms Number  
of patients
Median 
PFS 
(months)
Hazard 
ratio
p value Survival 
advantage
GOG 218(4) Arm 1: carboplatin + paclitaxel + placebo
Arm 2: carboplatin + paclitaxel + bevacizumab + placebo
Arm 3: carbolatin + paclitaxel + bevacizumab maintenance 
(15 months)
625
623
625
10.3
11.2
14.1
0.91
0.72
0.16
<0.0001
No
Patients with ascites
ICON7(5) Arm 1: carboplatin + paclitaxel
Arm 2: carboplatin + paclitaxel + bevacizumab maintenance 
(15 months)
764
764
22
24 0.81 0.004 Patients with a high 
risk of relapse
AURELIA(7) Arm 1: chemotherapy
Arm 2: chemotherapy + bevacizumab
182
179
3.8
6.7 0.48 0.001 No
OCEANS(6) Arm 1: carboplatin + gemcitabine + placebo
Arm 2: carboplatin + gemcitabine + bevacizumab to 
progression
242
242
8.4
12.4 0.48 <0.0001 No
GOG 213(8) Arm 1: paclitaxel + carboplatin
Arm 2: paclitaxel + carboplatin + bevacizumab; bevacizumab 
maintanance
374
374
10.4
13.8 0.61 0.056 Yes
Tab. 2. Summary of the four positive phase III trials adding bevacizumab to chemotherapy in epithelial ovarian carcinoma
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lower doses of bevacizumab used and the more favorable 
prognosis groups of patients. Angiogenesis inhibitors as 
initial therapy for advanced EOC are not recommended 
because only modest benefits have been demonstrated in 
randomized first-line trials(4,5,11,12) (Fig. 2).
BEVACIZUMAB AS SECOND-LINE 
TREATMENT FOR OVARIAN CANCER
Recurrent disease is typically not curable; therefore symp-
tom palliation and prevention of complications, such as 
bowel obstruction, remain the goals of management. How-
ever, for women who achieve a response or remission after 
platinum-based retreatment, the durability of the second 
remission is an important issue.
OCEANS is a  randomized trial of bevacizumab in 
484  women with platinum-sensitive recurrent ovarian 
cancer. Patients were randomized to receive carboplatin 
AUC (area under the curve) 4 on day 1 in combination with 
gemcitabine 1,000 mg/m2 on day 1 and 8 plus bevacizumab 
15 mg/kg or placebo on day 1, every 21 days. Bevacizumab 
or placebo was then continued until disease progression. 
An improvement in PFS (12 vs. 8 months, hazard ratio – 
HR 0.48, 95% CI 0.39–0.61) was observed. However, OS 
was not different between the two arms (34 vs. 33 months). 
The data consistently demonstrate that incorporating bev-
acizumab can improve PFS in women with platinum-sen-
sitive recurrent EOC. However, there has been no demon-
strable improvement in OS in this setting.
GOG 213 is a randomized open label phase III trial assess-
ing carboplatin and paclitaxel with or without 15 mg/kg 
of bevacizumab every 3 weeks followed by maintenance 
therapy(8). Chemotherapy alone, compared with chemo-
therapy plus bevacizumab, improved the stratified esti-
mated treatment HR of death by 18.6% (HR: 0.827, 95% 
CI: 0.683–1.005, p = 0.056) with median OS of 42.2 vs. 
37.3 months, respectively. PFS was similarly improved by 
adding bevacizumab to chemotherapy (median PFS 13.8 vs. 
10.4 months) (HR: 0.614, 95% CI: 0.522–0.722, p < 0.0001).
There are many important treatment-related issues to con-
sider in patients diagnosed with recurrent platinum-sensi-
tive cancer: what medications should be used and in what 
order? Could this simply be related to the chemotherapy 
backbone suggesting that carboplatin plus paclitaxel is 
better than carboplatin plus gemcitabine as a companion 
for bevacizumab?
There are many treatments available for recurrent ovar-
ian cancer. Combination of chemotherapy plus bevaci-
zumab is a  level 2B recommendation according to the 
National Comprehensive Cancer Network (NCCN) for 
patients with recurrent platinum-sensitive EOC (as per 
OCEANS)(12). Patients with platinum-resistant EOC are 
not curable. Hence, treatments should aim to maximize the 
quality of life while attempting to control the disease.
The AURELIA trial evaluated the impact of adding bev-
acizumab (10 mg/kg every 2 weeks or 15 mg/kg every 
3 weeks) to either dose-dense paclitaxel 80 mg/m2 weekly 
or topotecan 4 mg/m2 on days 1, 8, and 15 of each 4-week 
cycle (or 1.25 mg/m2 on day 1 through 5 of each 3-week 
cycle) or liposomal doxorubicin 40 mg/m2 every 4 weeks. 
Only patients with platinum-resistant ovarian cancer were 
eligible. Women at high risk for gastrointestinal (GI) perfo-
rations and patients who had more than 3 lines of prior che-
motherapy were excluded. A reduction in the risk of disease 
progression (HR 0.48, 95% CI 0.38–0.60; median duration 
6.7 vs. 3.4 months), with no statistically significant improve-
ment in OS (HR 0.85, 95% CI 0.66–1.08; median 16.6 vs. 
13.3 months) was observed (Fig. 3).
ADVERSE EFFECTS 
AND TOXICITY PROFILE 
OF BEVACIZUMAB IN OVARIAN CANCER
Will antiangiogenic drugs that have lethal effects on 
malignant growths while having minimal adverse effects 
on normal tissues ever be developed? Bowel perforation 
Fig. 2.  Incorporating bevacizumab into ovarian cancer treatment
Fig. 3.  The HRs were 0.72 and 0.93 for GOG 218 and ICON7, 
respectively, in first-line and 0.48 for both the OCEANS 
and AURELIA trials in relapse. The HRs was 0.61 for 
GOG 213
25
Progression-free survival
OCEANS AURELIA GOG 218 ICON7 GOG-213
20
15
10
5
0
CT
CT + BEV
HR
CT – chemotherapy, BEV – bevacizumab
Irem Bilgetekin, Bulent Cetin, Ahmet Ozet
82
CURR GYNECOL ONCOL 2017, 15 (1), p. 78–85DOI: 10.15557/CGO.2017.0007
or fistula formation may be more common in patients 
who are heavily pretreated or who have diffuse peritoneal 
disease or substantial pelvic disease with previous bowel 
surgery or bowel obstruction(13). Thus, bevacizumab is 
avoided in this population, especially because bowel per-
foration in such patients can be fatal. In GOG 218 trial, the 
risk of gastrointestinal perforation/fistula formation with 
and without bevacizumab was 3% vs. 1%(4). Similarly, low 
rates of gastrointestinal perforation were reported in the 
ICON7 trial of first line carboplatin plus paclitaxel with or 
without bevacizumab (1.7% vs. 1.3%)(5). In the OCEANS 
trial, there were no reported cases of gastrointestinal per-
foration, and the rates of fistula/abscess formation were 
also low in the bevacizumab group (4% vs. 1% in the con-
trol group, 1.6% vs. 0.4%)(6). In GOG 213 trial, the risk 
of gastrointestinal perforation/necrosis/fistula with and 
without bevacizumab was 1% vs. 1.8%, respectively(8). 
Bevacizumab has 3 black box warnings: gastrointestinal 
perforation, surgery and wound healing complications as 
well as severe or fatal hemorrhage including hemoptysis, 
gastrointestinal bleeding, central nervous system hem-
orrhage, and vaginal bleeding. Hypertension is common 
(20%), but arterial thromboembolic risk is estimated at 
3.8% compared with 1.7% for chemotherapy alone(14). 
Other toxicities include small (<1%) but potentially severe 
risk of grade 3 to 4 heart failure and reversible posterior 
leukoencephalopathy, both of which justify permanent 
bevacizumab discontinuation(14). Given that women with 
EOC often present or recur with peritoneal involvement, 
the risk of gastrointestinal perforation is of significant 
concern.
UNRESOLVED ISSUES IN THE USE  
OF BEVACIZUMAB IN OVARIAN CANCER
There are several unanswered questions regarding the 
use of bevacizumab in EOC. In view of the increasing use 
of bevacizumab in first-line regimens, an important clin-
ical issue is whether it should be continued in patients 
who switch to an alternative regimen after failing first-
line bevacizumab-containing therapy. There is evidence 
that bevacizumab can be used at all treatment stages. 
Bevacizumab as first line treatment does not preclude 
its use in recurrent disease(15). Re-treatment with bevaci-
zumab was not associated with a negative rebound effect 
in GOG 213. Re-introduction of bevacizumab was associ-
ated with a higher objective response rate and had no sig-
nificant impact on toxicity(16).
Should bevacizumab be used on its own or in combina-
tion? It is plausible that the synergistic effects of bevaci-
zumab with conventional chemotherapeutic drugs derive 
directly from the ability of this VEGF-A inhibitor to nor-
malize tumor-associated vasculature, thereby greatly facil-
itating the delivery of drugs to the tumor parenchyma(17).
This agent is frequently administered in the context of 
chemotherapy; however, several phase II trials evaluating 
its activity as a single agent have included patients with 
platinum-sensitive disease. In the GOG 170-D trial, 
11 responses (44%) were seen among 25 patients (41% of 
the total population) with potentially platinum-sensitive 
recurrent disease, including two complete responses(18). 
Future clinical developments of bevacizumab in ovar-
ian cancer treatment will include the combination of this 
agent with other targeted therapies in advanced disease 
and the integration of this agent into combined modal-
ity approaches for the treatment involving intraperitoneal 
chemotherapy and dose-dense chemotherapy.
NOVEL AGENTS: PAZOPANIB, 
NINTEDANIB AND TREBANANIB 
IN OVARIAN CANCER
Pazopanib is an oral tyrosine kinase inhibitor developed 
against VEGF, platelet-derived growth factor (PDGF) 
and c-kit receptor. The role of pazopanib in maintenance 
treatment was evaluated in AGO-OVAR study including 
900 EOC patients(19). The aim of this study was to deter-
mine whether therapy with pazopanib was effective and 
safe in women with epithelial ovarian, fallopian tube, or 
primary peritoneal cancer whose cancer did not progress 
on first line chemotherapy. Patients were randomized into 
pazopanib 800 mg daily and placebo arms for 24 months. 
Median PFS was significantly longer for pazopanib group 
(18 vs. 12  months, HR 0.766, 95% CI 0.64–0.91), but 
interim analysis showed no OS difference between the 
two arms. Pazopanib treatment was found to be associ-
ated with grade ≥2 hypertension (52% vs. 17%) grade 3 
or 4 diarrhea (8% vs. 1%) and grade 3 or 4 hepatotoxicity 
(9% vs. <1%). In conclusion, this study did not lead to any 
change in daily clinical practice.
Nintedanib is an oral tyrosine kinase inhibitor used 
against VEGF, fibroblast growth factor (FGF) and PDGF 
receptor. A phase III trial is investigating the combination 
of nintedanib with carboplatin and paclitaxel in the first-
line setting followed by nintedanib alone as maintenance 
therapy(20). Compared to placebo, nintedanib led to mod-
erate improvement in PFS (median 17.3 vs. 16.6 months, 
HR 0.84, 95% CI 0.72–0.98) and survival analysis is 
ongoing. Severe grade 3 to 5 toxicity including thrombo-
cytopenia, anemia, neutropenia, diarrhea, fatigue, hyper-
tension and hepatotoxicity was observed more frequently 
in nintedanib arm.
Trebananib  (AMG386) is an angiopoietin antagonist 
peptide-Fc fusion protein (also known as a peptibody) 
that inhibits Ang1 and Ang2 from binding to their tyro-
sine kinase receptors, leading to inhibition of angiogen-
esis(21). Ang1 stabilizes endothelial junction and Ang2 
leads to vessel sprouting in endothelium. They all increase 
vessel density(22). In phase III (TRINOVA-1) study includ-
ing 919 women, patients were randomized into pacli-
taxel and trebananib or placebo arms(23). The eligibility 
was limited to women with a platinum-free interval (PFI) 
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of  less than 12 months and allowed up to three prior 
anticancer therapies (22% of patients). The primary end 
point was PFS and the authors have recently reported 
that there was a significant improvement in PFS com-
pared with weekly paclitaxel plus placebo (median 7.2 
vs. 5.4 months, respectively, HR 0.66, 95% CI 0.57–0.77). 
When in November 2014, survival outcome of trebananib 
was compared with placebo, no significant difference was 
found (median 18 vs. 19 months)(24). When paclitaxel plus 
placebo was compared with paclitaxel plus trebananib, 
toxicity was shown to occur at higher rates: localized 
edema (57% vs. 26%), pleural effusion (13% vs. 4%), gener-
alized edema (11% vs. 3%), ascites (20% vs. 12%), periph-
eral neuropathy (21% vs. 16%).
Cediranib is an oral antiangiogenic VEGF receptor 
1–3 inhibitor. A phase III trial of platinum-based che-
motherapy (carboplatin plus paclitaxel) alone versus che-
motherapy with cediranib (as concurrent and/or main-
tenance therapy) in women with platinum-sensitive 
recurrent ovarian cancer was performed(25). The patients 
enrolled in cediranib-maintenance arm experienced 
longer PFS (HR 0.57, 95% CI 0.45–0.74, p  =  0.0024) 
and a 2.7-month improvement in OS (HR 0.70, 95% CI 
0.51–0.99, p = 0.042) when compared with those treated 
with chemotherapy alone. The most common cediranib-
related adverse events included diarrhea, nausea, and 
fatigue. We await final reporting of OS data from this 
study before altering our approach.
Aflibercept is a  fusion molecule containing the bind-
ing domains of VEGF receptors 1 and 2 bound to the 
human immunoglobulin IgG Fc fragment, forming 
a VEGF Trap molecule. It acts as a soluble “decoy” recep-
tor that binds to human VEGF-A, VEGF-B, and placen-
tal growth factor (PIGF), thereby inhibiting the binding 
of these ligands and activation of their respective recep-
tors. A randomized phase 2 study assessed the efficacy 
and safety of intravenous aflibercept at 2 different doses 
(2 mg/kg or 4 mg/kg) in patients with recurrent, plat-
inum-resistant ovarian, peritoneal, or fallopian tube 
cancer who developed disease progression after receiv-
ing topotecan and/or pegylated liposomal doxorubicin. 
The results were disappointing. Two-hundred and fifteen 
evaluable patients were analyzed, including 1 responder 
among 106 patients (0.9%) in the 2 mg/kg cohort, and 
5 responders among 109 patients (4.6%) in the 4 mg/kg 
cohort(26). In a double-blind, placebo-controlled, parallel-
group, phase 2 study, patients with advanced chemoresis-
tant ovarian cancer and recurrent symptomatic malignant 
ascites were randomly assigned to intravenous aflibercept 
(4 mg/kg every 2 weeks) or placebo arm. Mean time to 
repeated paracentesis was significantly longer with afliber-
cept (55.1 vs. 23.3 days; p = 0.0019)(27). Combination of this 
drug (6 mg/kg) and docetaxel (75 mg/m2) had signifi-
cant activity (54% response rate) in a phase I–II trial that 
included patients with platinum-sensitive as well as recur-
rent disease(28). None of these agents is currently approved 
by the US Food and Drug Administration for treating 
patients with relapsed ovarian cancer, and their ultimate 
value needs to be better defined.
RESISTANCE 
TO ANTIANGIOGENIC THERAPY
Resistance to VEGF inhibitors may be observed in late-
stage tumors when tumors regrow during treatment after 
the initial period of growth suppression from these antian-
giogenic agents. This resistance involves the reactivation of 
tumor angiogenesis and increased expression of other pro-
angiogenic factors. A fraction of tumor vessels are lined by 
malignant cells and are thus unresponsive to antiangio-
genic agents (vascular mimicry). The outgrowth of tumor 
cell clones expressing elevated levels of certain angiogenic 
factors may be naturally favored at advanced stages of 
tumor progression (angiogenic switch). For example, inhi-
bition of the VEGF pathway leads to resumption of tumor 
angiogenesis through upregulation of fibroblast growth 
factor-2 (FGF2)(29), interleukin-8(30), and Ang2(31).
Mutant tumor cell clones (e.g. those lacking p53) are able 
to survive in hypoxic tumors (vascular independence). 
Preexisting vessels are covered by a full complement of 
supporting pericytes and are unable to maintain vascular 
regression induced by antiangiogenic treatments. Tumors 
or ischemic tissues recruit proangiogenic endothelial 
cells and inflammatory cells independent of VEGF; the 
recruited cells may produce several proangiogenic mole-
cules to rescue vascularization upon VEGF blockage.
CONCLUSION
EOC remains an important problem worldwide. The major-
ity of patients with ovarian cancer will require palliative 
treatment at some point in the course of their disease. 
Tumor angiogenesis remains a critical target for the treat-
ment of patients with ovarian cancer. There was no consen-
sus regarding the incorporation of bevacizumab in first line 
therapy trials. The NCCN Panel recommends (category 2B) 
bevacizumab in upfront chemotherapy followed by main-
tenance therapy(12).
On the other hand, the European Society for Medical Oncol-
ogy (ESMO) Clinical Practice Guidelines recommends (cat-
egory IB) bevacizumab in patients with advanced ovarian 
cancer with poor prognostic factors such as stage IV or sub-
optimal debulking as defined in the ICON7 trial(2). In recent 
years, a better understanding of the biological properties of 
tumors and the development and application of molecu-
lar targeted drugs have created hope for the individualized 
treatment of advanced ovarian cancer.
Future perspective
We still do not understand how cancer cells create metas-
tases that are responsible for 90% of cancer-associated 
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mortality. With enhanced understanding of vascular 
biology and advances in targeted therapy design, medi-
cal oncology practice will see an expanding role of tumor 
endothelial directed therapies. And while we know much 
about the individual signaling molecules operating inside 
individual human cells, we lack a clear understanding of 
how the complex signaling circuitry formed by these mol-
ecules makes the life and death decisions that determine 
the fate of individual cells within our body. Although 
antiangiogenic drugs improved PFS and, in some cases, 
OS, phase 3 trials showed that the benefits were clinically 
modest. More importantly, these studies would represent 
a major step forward in the field of targeted antiangiogen-
esis therapies which is tremendously important for oncol-
ogy and encourage further molecular and clinical studies 
to identify reliable biomarkers suitable for use in the clin-
ical setting and to provide increased benefits from thera-
pies targeting angiogenesis with selection of appropriate 
patients. A first prospective biomarker study (MERiDiAN) 
in metastatic breast cancer is currently underway to eval-
uate the impact of bevacizumab in patients stratified for 
plasma short VEGF-A isoforms. If validated, these find-
ings could help identify which subgroup of patients should 
receive antiangiogenic therapy and could lead the way to 
possible future tailoring of individualized antiangiogenic 
therapy.  It is likely that our current understanding of 
tumor angiogenesis and our ability to manipulate it clini-
cally will have once again been greatly altered by the next 
edition of this review.
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